NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis

Iovance Biotherapeutics, Inc. (IOVA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IOVA

$8.79

+$0.09 (+1.03%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IOVA with… →

IOVA Key Statistics

As of Sep 4, 2026
Trading
Open
$8.74
Previous Close
$8.70
Day's Range
8.64–8.90
52-Week Range
1.76–9.36
Volume
8.07M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.83
Valuation
Market Cap
$3.98B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
12.25
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.70
Financials (FY)
Revenue (FY)
$263.50M+60.60%
Net Income (FY)
−$390.98M
Profit marginThe share of revenue left as profit after all costs and taxes.
−89.09%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
452.97M
1-Year Return
+299.55%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
16.31M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IOVA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+221.98%
2025−63.11%
2024−8.98%
2023+27.23%
2022−66.53%
2021−58.86%
2020+67.63%
2019+212.77%
2018+10.62%
2017+15.11%
2016 (partial year)−24.54%

As of September 4, 2026.

IOVA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$263.50M−$390.98M−148.4%
2024$164.07M−$372.18M−226.8%
2023$1.19M−$444.04M−37345.4%
2022$0.00−$395.89M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$263.50M$90.32M−$398.21M−$390.98M−148.4%
2024$164.07M$70.82M−$395.28M−$372.18M−226.8%
2023$1.19M$156.00K−$460.56M−$444.04M−37345.4%
2022$0.00$0.00−$398.88M−$395.89M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IOVA Valuation vs Biotechnology Median

Median of 656 stocks
MetricIOVABiotechnology medianvs median
P/S ratio12.2515.2620% below
Profit margin−89.09%0.00%89.1 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Iovance Biotherapeutics, Inc. (IOVA) is capitalised at $3.98B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 975 employees.

Over the past 52 weeks the price has ranged from $1.76 to $9.36. The most recent close on file for IOVA is $8.79, dated September 4, 2026. That is +$0.09 (+1.03%) against the previous close. The latest close sits 399.43% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $263.50M. Against the prior fiscal year total of $164.07M, that is a change of +60.60%. The same year closed with a net loss of $390.98M. The reported profit margin is −89.09%. That is 89.1 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −0.7.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $263.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 12.25. On price-to-sales that is 19.73% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 0.83. Annualized volatility over the trailing 10 years is 83.29%. The trailing one-year price return is +299.55%. Across 10 years the annualized return works out at +0.98%.

Growth & Income

No dividend is on file for IOVA.

2026 is still running; the price is +221.98% year to date. The strongest complete calendar year on file is 2019 at +212.77%; the weakest is 2022 at −66.53%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Iovance Biotherapeutics, Inc. (IOVA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Iovance Biotherapeutics, Inc. IOVA $3.98B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Iovance Biotherapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Visit website →